Actively Recruiting

Age: 18Years - 70Years
All Genders
NCT06197776

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Led by Sun Yat-sen University · Updated on 2026-05-11

50

Participants Needed

1

Research Sites

228 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The observational clinical study will recruit 50 recurrent and/or metastatic nasopharyngeal carcinoma (r/mNPC) patients, to investigate the prediction values of multi-omics technique for the efficacy of chemoradiotherapy combined with immunotherapy.

CONDITIONS

Official Title

Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Recurrent or metastatic nasopharyngeal carcinoma patients
  • All genders, aged 18 to 70 years
  • ECOG performance status score of 0 to 1
  • Signed informed consent form
Not Eligible

You will not qualify if you...

  • Having or currently suffering from other malignant tumors
  • Participating in other clinical trials
  • Drug or alcohol addiction
  • Lack of full legal capacity
  • Mental disorder
  • Pregnancy or breastfeeding
  • Severe complications such as uncontrolled hypertension

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Cancer Center, Sun Yat-sen University

Guangzhou, Guangdong, China

Actively Recruiting

Loading map...

Research Team

J

Jingjing Miao, M.D

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here